HRI researchers Dr Amelia Tomkins (Thrombosis) and Bradley Tucker (Cell Therapeutics) presented their Groups’ latest works, while some sessions were chaired by Associate Professor Simone Schoenwaelder (Thrombosis) and Dr Mary Kavurma (Group Leader, Vascular Complications).
Dr Tomkins presented the Thrombosis Group’s development of a new stroke model for the purposes of better testing novel stroke therapies. This model has an advantage over current models as it enables direct assessment of the therapeutic-induced reopening of a blocked artery that causes stroke. In combination, this enables the assessment of the effect of blood flow reduction in the brain and the final stroke outcomes of brain injury and functional recovery. The researchers believe this model will provide a better understanding of the efficacy of new therapies for stroke.
“It was also a great opportunity to talk with colleagues in the field and perhaps pave the way for future collaborations,” she says.
Mr Tucker presented results regarding the role of colchicine in modulating vascular inflammation in the setting of coronary heart disease. The research suggests the anti-inflammatory effects of colchicine may be partially due to reduced leukocyte infiltration.
“The conference was very well organised and presented a wonderful opportunity to network with like-minded scientists,” Mr Tucker says.
Our Thrombosis Group is conducting groundbreaking research to discover new ways to prevent heart attack and stroke, with the focus on blood clots. But to continue this vital work, we need your help.
A breakthrough by HRI scientists could soon protect tens of thousands of Australians with diabetes from killer heart disease and stroke.
HRI scientists attended and presented at the inaugural Mechanobiology Down Under meeting, which was recently held at the Bronte Surf Lifesaving Club in Sydney on 3–4 May 2018.